Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

Journal article

Currently, there are no reliably effective therapeutic options for metastatic pheochromocytoma (PCC) and paraganglioma. Moreover, there are no therapies that may prevent the onset or progression of tumors in patients with succinate dehydrogenase type B mutations, which are associated with very aggressive tumors. Therefore, we tested the approved and well-tolerated drugs lovastatin and 13-cis-retinoic acid (13cRA) in vitro in an aggressive PCC mouse cell line, mouse tumor tissue-derived (MTT) ...

Expand abstract

Authors: Nölting, S; Giubellino, A; Tayem, Y; Young, K; Lauseker, M

• Publication status: Published
• Publisher: Endocrine Society
• Journal: Endocrinology
• Volume: 155
• Issue: 7
• Pages: 2377-2390
• Publication date: 2014-07-01
• DOI: 10.1210/en.2014-1027
• EISSN: 1945-7170
• ISSN: 0013-7227
• Language: English
• Keywords: Animals; Actins; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols; Immunohistochemistry; Antigens, CD34; Adrenal Gland Neoplasms; Mice; Chromogranin A; Pheochromocytoma; Muscle, Smooth; Tumor Burden; Cell Survival; Lovastatin; Cell Line, Tumor; Female; Tyrosine 3-Monooxygenase; Mice, Nude; Time Factors; Isotretinoin; Lung Neoplasms; Transplantation, Homologous